Your browser doesn't support javascript.
loading
Importancia de los estudios de seguridad tras la comercialización de un fármaco: el ejemplo de los inhibidores de la dipeptidil peptidasa-4 en pacientes con insuficiencia cardiaca / No disponible
Gallego Muñoz, Cristóbal; Ferreira Alfaya, Francisco Javier; Guerrero Navarro, Nieves.
Affiliation
  • Gallego Muñoz, Cristóbal; Hospital Reina Sofía. Murcia. España
  • Ferreira Alfaya, Francisco Javier; Universidad de Granada. Granada. España
  • Guerrero Navarro, Nieves; Hospital Nuestra Señora de la Merced. Osuna. España
Ars pharm ; 58(3): 91-93, jul.-sept. 2017.
Article in Es | IBECS | ID: ibc-168843
Responsible library: ES1.1
Localization: BNCS
RESUMEN
No disponible
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Drug-Related Side Effects and Adverse Reactions / Dipeptidyl-Peptidase IV Inhibitors / Heart Failure Limits: Humans Language: Es Journal: Ars pharm Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Drug-Related Side Effects and Adverse Reactions / Dipeptidyl-Peptidase IV Inhibitors / Heart Failure Limits: Humans Language: Es Journal: Ars pharm Year: 2017 Document type: Article